From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours
Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bajetta, Emilio [verfasserIn] Procopio, Giuseppe [verfasserIn] Pusceddu, Sara [verfasserIn] Pietrantonio, Filippo [verfasserIn] Milione, Massimo [verfasserIn] Maccauro, Marco [verfasserIn] Verzoni, Elena [verfasserIn] Guadalupi, Valentina [verfasserIn] Platania, Marco [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2009 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Oncology reviews - Pavia : PAGEPress, 2007, 3(2009), 2 vom: 14. Mai, Seite 79-87 |
|---|---|
| Übergeordnetes Werk: |
volume:3 ; year:2009 ; number:2 ; day:14 ; month:05 ; pages:79-87 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12156-009-0011-x |
|---|
| Katalog-ID: |
SPR024529133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR024529133 | ||
| 003 | DE-627 | ||
| 005 | 20230519154620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201006s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12156-009-0011-x |2 doi | |
| 035 | |a (DE-627)SPR024529133 | ||
| 035 | |a (SPR)s12156-009-0011-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Bajetta, Emilio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. | ||
| 650 | 4 | |a Neuroendocrine tumours |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Angiogenesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Target therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Procopio, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Pusceddu, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantonio, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Milione, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Maccauro, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Verzoni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Guadalupi, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Platania, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology reviews |d Pavia : PAGEPress, 2007 |g 3(2009), 2 vom: 14. Mai, Seite 79-87 |w (DE-627)546500935 |w (DE-600)2390305-3 |x 1970-5565 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2009 |g number:2 |g day:14 |g month:05 |g pages:79-87 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12156-009-0011-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2009 |e 2 |b 14 |c 05 |h 79-87 | ||
| author_variant |
e b eb g p gp s p sp f p fp m m mm m m mm e v ev v g vg m p mp |
|---|---|
| matchkey_str |
article:19705565:2009----::rmilgtciiaepreceouinnhkoldef |
| hierarchy_sort_str |
2009 |
| publishDate |
2009 |
| allfields |
10.1007/s12156-009-0011-x doi (DE-627)SPR024529133 (SPR)s12156-009-0011-x-e DE-627 ger DE-627 rakwb eng 610 ASE Bajetta, Emilio verfasserin aut From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 Procopio, Giuseppe verfasserin aut Pusceddu, Sara verfasserin aut Pietrantonio, Filippo verfasserin aut Milione, Massimo verfasserin aut Maccauro, Marco verfasserin aut Verzoni, Elena verfasserin aut Guadalupi, Valentina verfasserin aut Platania, Marco verfasserin aut Enthalten in Oncology reviews Pavia : PAGEPress, 2007 3(2009), 2 vom: 14. Mai, Seite 79-87 (DE-627)546500935 (DE-600)2390305-3 1970-5565 nnns volume:3 year:2009 number:2 day:14 month:05 pages:79-87 https://dx.doi.org/10.1007/s12156-009-0011-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 AR 3 2009 2 14 05 79-87 |
| spelling |
10.1007/s12156-009-0011-x doi (DE-627)SPR024529133 (SPR)s12156-009-0011-x-e DE-627 ger DE-627 rakwb eng 610 ASE Bajetta, Emilio verfasserin aut From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 Procopio, Giuseppe verfasserin aut Pusceddu, Sara verfasserin aut Pietrantonio, Filippo verfasserin aut Milione, Massimo verfasserin aut Maccauro, Marco verfasserin aut Verzoni, Elena verfasserin aut Guadalupi, Valentina verfasserin aut Platania, Marco verfasserin aut Enthalten in Oncology reviews Pavia : PAGEPress, 2007 3(2009), 2 vom: 14. Mai, Seite 79-87 (DE-627)546500935 (DE-600)2390305-3 1970-5565 nnns volume:3 year:2009 number:2 day:14 month:05 pages:79-87 https://dx.doi.org/10.1007/s12156-009-0011-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 AR 3 2009 2 14 05 79-87 |
| allfields_unstemmed |
10.1007/s12156-009-0011-x doi (DE-627)SPR024529133 (SPR)s12156-009-0011-x-e DE-627 ger DE-627 rakwb eng 610 ASE Bajetta, Emilio verfasserin aut From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 Procopio, Giuseppe verfasserin aut Pusceddu, Sara verfasserin aut Pietrantonio, Filippo verfasserin aut Milione, Massimo verfasserin aut Maccauro, Marco verfasserin aut Verzoni, Elena verfasserin aut Guadalupi, Valentina verfasserin aut Platania, Marco verfasserin aut Enthalten in Oncology reviews Pavia : PAGEPress, 2007 3(2009), 2 vom: 14. Mai, Seite 79-87 (DE-627)546500935 (DE-600)2390305-3 1970-5565 nnns volume:3 year:2009 number:2 day:14 month:05 pages:79-87 https://dx.doi.org/10.1007/s12156-009-0011-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 AR 3 2009 2 14 05 79-87 |
| allfieldsGer |
10.1007/s12156-009-0011-x doi (DE-627)SPR024529133 (SPR)s12156-009-0011-x-e DE-627 ger DE-627 rakwb eng 610 ASE Bajetta, Emilio verfasserin aut From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 Procopio, Giuseppe verfasserin aut Pusceddu, Sara verfasserin aut Pietrantonio, Filippo verfasserin aut Milione, Massimo verfasserin aut Maccauro, Marco verfasserin aut Verzoni, Elena verfasserin aut Guadalupi, Valentina verfasserin aut Platania, Marco verfasserin aut Enthalten in Oncology reviews Pavia : PAGEPress, 2007 3(2009), 2 vom: 14. Mai, Seite 79-87 (DE-627)546500935 (DE-600)2390305-3 1970-5565 nnns volume:3 year:2009 number:2 day:14 month:05 pages:79-87 https://dx.doi.org/10.1007/s12156-009-0011-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 AR 3 2009 2 14 05 79-87 |
| allfieldsSound |
10.1007/s12156-009-0011-x doi (DE-627)SPR024529133 (SPR)s12156-009-0011-x-e DE-627 ger DE-627 rakwb eng 610 ASE Bajetta, Emilio verfasserin aut From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 Procopio, Giuseppe verfasserin aut Pusceddu, Sara verfasserin aut Pietrantonio, Filippo verfasserin aut Milione, Massimo verfasserin aut Maccauro, Marco verfasserin aut Verzoni, Elena verfasserin aut Guadalupi, Valentina verfasserin aut Platania, Marco verfasserin aut Enthalten in Oncology reviews Pavia : PAGEPress, 2007 3(2009), 2 vom: 14. Mai, Seite 79-87 (DE-627)546500935 (DE-600)2390305-3 1970-5565 nnns volume:3 year:2009 number:2 day:14 month:05 pages:79-87 https://dx.doi.org/10.1007/s12156-009-0011-x lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 AR 3 2009 2 14 05 79-87 |
| language |
English |
| source |
Enthalten in Oncology reviews 3(2009), 2 vom: 14. Mai, Seite 79-87 volume:3 year:2009 number:2 day:14 month:05 pages:79-87 |
| sourceStr |
Enthalten in Oncology reviews 3(2009), 2 vom: 14. Mai, Seite 79-87 volume:3 year:2009 number:2 day:14 month:05 pages:79-87 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Neuroendocrine tumours Angiogenesis Metastasis Chemotherapy Target therapy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Oncology reviews |
| authorswithroles_txt_mv |
Bajetta, Emilio @@aut@@ Procopio, Giuseppe @@aut@@ Pusceddu, Sara @@aut@@ Pietrantonio, Filippo @@aut@@ Milione, Massimo @@aut@@ Maccauro, Marco @@aut@@ Verzoni, Elena @@aut@@ Guadalupi, Valentina @@aut@@ Platania, Marco @@aut@@ |
| publishDateDaySort_date |
2009-05-14T00:00:00Z |
| hierarchy_top_id |
546500935 |
| dewey-sort |
3610 |
| id |
SPR024529133 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024529133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519154620.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12156-009-0011-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024529133</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12156-009-0011-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bajetta, Emilio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroendocrine tumours</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiogenesis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Target therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Procopio, Giuseppe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pusceddu, Sara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pietrantonio, Filippo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Milione, Massimo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maccauro, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verzoni, Elena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guadalupi, Valentina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Platania, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Oncology reviews</subfield><subfield code="d">Pavia : PAGEPress, 2007</subfield><subfield code="g">3(2009), 2 vom: 14. Mai, Seite 79-87</subfield><subfield code="w">(DE-627)546500935</subfield><subfield code="w">(DE-600)2390305-3</subfield><subfield code="x">1970-5565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">day:14</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:79-87</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12156-009-0011-x</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="b">14</subfield><subfield code="c">05</subfield><subfield code="h">79-87</subfield></datafield></record></collection>
|
| author |
Bajetta, Emilio |
| spellingShingle |
Bajetta, Emilio ddc 610 misc Neuroendocrine tumours misc Angiogenesis misc Metastasis misc Chemotherapy misc Target therapy From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| authorStr |
Bajetta, Emilio |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)546500935 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1970-5565 |
| topic_title |
610 ASE From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours Neuroendocrine tumours (dpeaa)DE-He213 Angiogenesis (dpeaa)DE-He213 Metastasis (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Target therapy (dpeaa)DE-He213 |
| topic |
ddc 610 misc Neuroendocrine tumours misc Angiogenesis misc Metastasis misc Chemotherapy misc Target therapy |
| topic_unstemmed |
ddc 610 misc Neuroendocrine tumours misc Angiogenesis misc Metastasis misc Chemotherapy misc Target therapy |
| topic_browse |
ddc 610 misc Neuroendocrine tumours misc Angiogenesis misc Metastasis misc Chemotherapy misc Target therapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Oncology reviews |
| hierarchy_parent_id |
546500935 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Oncology reviews |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)546500935 (DE-600)2390305-3 |
| title |
From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| ctrlnum |
(DE-627)SPR024529133 (SPR)s12156-009-0011-x-e |
| title_full |
From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| author_sort |
Bajetta, Emilio |
| journal |
Oncology reviews |
| journalStr |
Oncology reviews |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2009 |
| contenttype_str_mv |
txt |
| container_start_page |
79 |
| author_browse |
Bajetta, Emilio Procopio, Giuseppe Pusceddu, Sara Pietrantonio, Filippo Milione, Massimo Maccauro, Marco Verzoni, Elena Guadalupi, Valentina Platania, Marco |
| container_volume |
3 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bajetta, Emilio |
| doi_str_mv |
10.1007/s12156-009-0011-x |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
from biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_auth |
From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| abstract |
Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. |
| abstractGer |
Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. |
| abstract_unstemmed |
Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2006 GBV_ILN_2010 GBV_ILN_2020 GBV_ILN_2057 GBV_ILN_2190 |
| container_issue |
2 |
| title_short |
From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| url |
https://dx.doi.org/10.1007/s12156-009-0011-x |
| remote_bool |
true |
| author2 |
Procopio, Giuseppe Pusceddu, Sara Pietrantonio, Filippo Milione, Massimo Maccauro, Marco Verzoni, Elena Guadalupi, Valentina Platania, Marco |
| author2Str |
Procopio, Giuseppe Pusceddu, Sara Pietrantonio, Filippo Milione, Massimo Maccauro, Marco Verzoni, Elena Guadalupi, Valentina Platania, Marco |
| ppnlink |
546500935 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12156-009-0011-x |
| up_date |
2024-07-04T01:19:23.658Z |
| _version_ |
1803609402150748161 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024529133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519154620.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12156-009-0011-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024529133</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12156-009-0011-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bajetta, Emilio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroendocrine tumours</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiogenesis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Target therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Procopio, Giuseppe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pusceddu, Sara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pietrantonio, Filippo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Milione, Massimo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maccauro, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verzoni, Elena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guadalupi, Valentina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Platania, Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Oncology reviews</subfield><subfield code="d">Pavia : PAGEPress, 2007</subfield><subfield code="g">3(2009), 2 vom: 14. Mai, Seite 79-87</subfield><subfield code="w">(DE-627)546500935</subfield><subfield code="w">(DE-600)2390305-3</subfield><subfield code="x">1970-5565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">day:14</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:79-87</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12156-009-0011-x</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="b">14</subfield><subfield code="c">05</subfield><subfield code="h">79-87</subfield></datafield></record></collection>
|
| score |
7.397253 |